Could a lung scarring drug ease rare windpipe narrowing?
NCT ID NCT07654517
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This study tests if pirfenidone, a drug used for lung scarring, can safely slow scar buildup in the windpipe of people with idiopathic subglottic stenosis (iSGS). About 40 adults will receive either pirfenidone or a placebo for one year, alongside their usual steroid injections. The main goal is to check safety and tolerability, while also looking for signs that the drug may delay the need for airway dilation procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC SUBGLOTTIC STENOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Schulich School of Medicine and Dentistry
London, Ontario, N6A 4L6, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.